Real word outcomes associated with use of raltegravir in older people living with HIV: results from the 60 months follow-up of the RAL-age cohort

References

• UNAIDS. Get on the fast-track, the life-cycle approach to HIV. 2016 [cited 2017 Oct 10]. Available from: http://www.unaids.org/sites/default/files/media_asset/Get-on-the-Fast-Track_en.pdf
   Google Scholar
• Harris TG, Rabkin M, El-Sadr WM. Achieving the fourth 90: healthy aging for people living with HIV. AIDS. 2018;32(12):1563–1569.
   PubMed Web of Science ®Google Scholar
• High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH office of AIDS research by the HIV and aging working group. J Acquir Immune Defic Syndr. 2012;60(Suppl 1):S1–18.
   PubMed Web of Science ®Google Scholar
• van Sighem AI, Gras LA, Reiss P, et al. ATHENA national observational cohort study: life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24:1527–1535.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172.
   PubMed Web of Science ®Google Scholar
• d’Ettorre G, Ceccarelli G, Giustini N, et al. Taming HIV-related inflammation with physical activity: a matter of timing. AIDS Res Hum Retroviruses. 2014;30(10):936–944.
   PubMed Web of Science ®Google Scholar
• Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214:231–241.
   PubMed Web of Science ®Google Scholar
• Vanderford TH, Adamski J, Silvestri G. HIV-associated chronic immune activation: current understandings and therapeutic intervention. Future Med. 2010;4:161–177.
   Google Scholar
• d’Ettorre G, Paiardini M, Ceccarelli G, et al. HIV-associated immune activation: from bench to bedside. AIDS Res Hum Retroviruses. 2011;27:355–364.
   PubMed Web of Science ®Google Scholar
• Farahani M, Mulinder H, Farahani A, et al. Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy: a systematic review and meta-analysis. Int J STD AIDS. 2017;28(7):636–650.
   PubMed Web of Science ®Google Scholar
• Casper C, Crane H, Menon M, et al. HIV/AIDS comorbidities: impact on cancer, noncommunicable diseases, and reproductive health. In: Holmes KK, Bertozzi S, Bloom BR, et al., editors. Major infectious diseases. 3rd ed. Washington (DC): The International Bank for Reconstruction and Development/The World Bank; 2017 Nov 3. Chapter 3:1–3.
   Google Scholar
• Deeken JF, Tjen-A-Looi A, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis. 2012;55(9):1228–1235.
   PubMed Web of Science ®Google Scholar
• Ministero della Salute – SIMIT. Linee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1 - anno 2017. 2017 [cited 2019 Oct 24]. Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2696_allegato.pdf
   Google Scholar
• Pavone P, Giustini N, Fimiani C, et al. Long-term treatment with Raltegravir is associated with lower triglycerides and platelets count in the older HIV+ population: results from the Ral-Age study. Curr HIV Res. 2017;15(5):355–360.
   PubMed Web of Science ®Google Scholar
• Harari S. Randomised controlled trials and real-life studies: two answers for one question. Eur Respir Rev. 2018;27(149):pii: 180080.
   Web of Science ®Google Scholar
• Webster J, Smith BD. The case for real-world evidence in the future of clinical research on chronic myeloid leukemia. Clin Ther. 2019;41(2):336–349.
   PubMed Web of Science ®Google Scholar
• Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;11:295–304.
   PubMed Web of Science ®Google Scholar
• Klonoff DC. The new FDA real-world evidence program to support development of drugs and biologics. J Diabetes Sci Technol. 2019 Mar 12:1932296819832661.
   Google Scholar
• Adamson J, Hewitt CE, Torgerson DJ. Producing better evidence on how to improve randomised controlled trials. BMJ. 2015;351:h4923.
   PubMedGoogle Scholar
• d’Arminio Monforte A, Cozzi-Lepri A, Di Biagio A, et al. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. J Antimicrob Chemother. 2019;74(5):1363–1367.
   PubMed Web of Science ®Google Scholar
• Martínez E, D’Albuquerque PM, Llibre JM, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS. 2012;26(18):2315–2326.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375:396–407.
   PubMed Web of Science ®Google Scholar
• Martınez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010 29;24:1697–1707.
   PubMed Web of Science ®Google Scholar
• Curran A, Martinez E, Saumoy M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS. 2012;26:475–481.
   PubMed Web of Science ®Google Scholar
• Funderburg NT, Andrade A, Chan ES, et al. Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine. PLoS One. 2013;8(12):e83514.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Tran TT, Stein JH, et al. Changes in Inflammation and Immune activation with Atazanavir-, Raltegravir-, Darunavir-based initial antiviral therapy: ACTG 5260s. Clin Infect Dis. 2015;61(4):651–660.
   PubMed Web of Science ®Google Scholar
• Sloan A, Gona P, Johnson AD. Cardiovascular correlates of platelet count and volume in the Framingham heart study. Ann Epidemiol. 2015;25(7):492–498.
   PubMed Web of Science ®Google Scholar
• Mayne E, Funderburg NT, Sieg SF, et al. Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr. 2012;59(4):340–346.
   PubMed Web of Science ®Google Scholar
• Laurence J, Elhadad S, Ahamed J. HIV-associated cardiovascular disease: importance of platelet activation and cardiac fibrosis in the setting of specific antiretroviral therapies. Open Heart. 2018;5:e000823.
   PubMed Web of Science ®Google Scholar
• van der Heijden WA, van Crevel R, de Groot PG, et al. A switch to a raltegravir containing regimen does not lower platelet reactivity in HIV-infected individuals. AIDS. 2018;32(17):2469–2475.
   PubMed Web of Science ®Google Scholar
• van Halsema C, Whitfield T, Lin N, et al. Five years’ real-life experience with raltegravir in a large HIV centre. Int J STD AIDS. 2016;27(5):387–393.
   PubMed Web of Science ®Google Scholar
• Jaeckle M, Khaykin P, Haberl A, et al. Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice. Int J STD AIDS. 2016;27(13):1170–1179.
   PubMed Web of Science ®Google Scholar
• Naumann U, Moll A, Schleehauf D, et al. Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: real-life analysis of the German ‘WIP’ cohort. Int J STD AIDS. 2017;28(9):893–901.
   PubMed Web of Science ®Google Scholar
• Peñafiel J, de Lazzari E, Padilla M, et al. Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother. 2017;72(6):1752–1759.
   PubMed Web of Science ®Google Scholar
• Naumann U, Moll A, Schleehauf D, et al. Safety analysis of German real-life cohort WIP shows rates of neuropsychiatric events leading to discontinuation of raltegravir therapy below 2. Int J STD AIDS. 2019;30(7):727–728.
   PubMed Web of Science ®Google Scholar
• Spire B, Nait-Ighil L, Pugliese P, et al. Quality of life improvement in HIV-1 patients treated with raltegravir in a real-life observational study: RACING. HIV Clin Trials. 2017;18(1):1–16.
   PubMed Web of Science ®Google Scholar
• Bartlett VL, Dhruva SS, Shah ND, et al. Feasibility of using real-world data to replicate clinical trial evidence. JAMA Network Open. 2019;2(10):e1912869.
   PubMed Web of Science ®Google Scholar